William M. Sikov

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology · 2018 · 744 citations

Breast Oncology, Parp Inhibitor Veliparib, Medicine +7

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Marjorie C. Green, Aman U. Buzdar, Terry Smith et al. · Journal of Clinical Oncology · 2005 · 418 citations

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for<i>HER2 (ERBB2)</i>–Positive Breast Cancer

Nathaniel Braman, Prateek Prasanna, Jon Whitney et al. · JAMA Network Open · 2019 · 319 citations · Full text

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Charles E. Geyer, William M. Sikov, Jens Huober et al. · Annals of Oncology · 2022 · 199 citations · Full text